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ABSTRACT Treatment of advanced melanoma with selective BRAF and MEK inhibi-
tors is associated with a series of mucocutaneous side effects, among which mor-
phological changes in preexisting nevi and the development of new melanocytic 
lesions, both benign and malignant.
Objective was to describe the changes observed in melanocytic nevi under vemu-
rafenib therapy, followed by combination therapy with dabrafenib and trametinib 
for metastatic melanoma.
The melanocytic lesions of a 51-year-old Caucasian male patient diagnosed with 
stage IV melanoma were monitored both clinically and dermoscopically throughout 
vemurafenib, followed by combined treatment with dabrafenib and trametinib.
The 65 monitored nevi presented different behaviors under vemurafenib treat-
ment: 18 reticular nevi, 9 reticular-homogenous nevi, 3 reticular-globular nevi, and 
2 globular nevi showed a diffuse decrease in pigmentation. Ten reticular nevi re-
mained unchanged, while the rest of the nevi, independent of the dermoscopic 
pattern, presented a gradual increase in pigmentation. On the other hand, under 
dabrafenib and trametinib treatment 57 of these nevi showed gradual decrease in 
pigmentation and central involution, while 7 reticular nevi and 1 globular nevus 
remained unchanged; none of the monitored nevi increased in pigmentation nor 
presented new globules following this combination therapy.
Systematic total body skin examination is mandatory in patients receiving BRAF 
inhibitors. The divergent course of melanocytic nevi during vemurafenib vs. dab-
rafenib and trametinib therapy remains to be elucidated by further research.
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INTRODUCTION
Despite global efforts to prevent melanoma 
through education campaigns and melanoma 
screening programs, its incidence has constantly ris-
en during the last few decades (1-3). It accounts for 
less than 2% of skin cancers, but is responsible for ap-
proximately 75% of deaths from skin cancer (1).
Melanoma is a curable disease when detected 
early. However, with regard to advanced metastatic 
melanoma we are faced with few therapeutic options 
and a very high mortality rate. Inclusion of patients 
with stage IV melanoma in clinical trials is preferred 
due to the low response rate to standard chemother-
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apeutic agents such as dacarbazine (as monotherapy 
or combined with carmustine and cisplatin) and to 
immunotherapeutic agents such as interferon alpha-
2b and high dose interleukin 2. All these treatments 
failed to improve overall survival in stage IV melano-
ma, although the latter was associated with durable 
complete responses in a minority of patients.
Recently, 4 innovative therapeutic agents resulted 
in improved rates of overall and progression-free sur-
vival in patients with advanced melanoma in phase III 
clinical trials (4,5). 
Ipilimumab, a fully human monoclonal antibody 
against the cytotoxic T lymphocyte associated anti-
gen 4 (CTLA 4) proved beneficial both as single ther-
apy in patients with pretreated metastatic melanoma 
and in combination with dacarbazine in patients with 
previously untreated metastatic melanoma (6). It was 
approved by the US Food and Drug Administration 
(FDA) for the treatment of unresectable metastatic 
melanoma in March 2011 and by the European Medi-
cines Agency (EMA) as the second line treatment for 
metastatic melanoma in November 2012 (7,8).
Vemurafenib, a BRAF serine-threonine kinase 
inhibitor, was approved by the FDA in August 2011 
and by the EMA in February 2012 for the treatment of 
unresectable or metastatic melanoma harboring the 
activating BRAF V600E mutation. This is the most fre-
quent protein kinase mutation encountered in mela-
noma, resulting from the substitution of valine (V) by 
glutamic acid (E) at codon 600 on the BRAF protein 
(9). Compared to the wild type, BRAF V600E has a sig-
nificantly intensified kinase activity associated with 
uncontrolled cell growth and prolonged cell survival 
(10-12). Approximately 50% of melanomas and an 
even higher percentage of melanocytic nevi exhibit 
activating BRAF mutations (11,12). Vemurafenib does 
not inhibit melanoma cells without this mutation and 
can even stimulate wild type BRAF, promoting tumor 
growth (13,14). Clinical trials have shown that mela-
noma regresses at least to some degree in up to 90 
% of patients treated with vemurafenib (15-17). The 
phase III trial that compared the effects of vemu-
rafenib 960 mg orally twice daily and dacarbazine 
1000 mg/m2 of body surface area administered intra-
venously every 3 weeks in 675 previously untreated 
patients with metastatic melanoma positive for BRAF 
V600E mutation demonstrated significant improve-
ment in median overall survival (13.6 months vs. 9.7 
months, hazard ratio=0.7) and progression-free sur-
vival (5.3 vs. 1.6 months; hazard ratio=0.26, p\0.001) 
in patients treated with vemurafenib (15). The overall 
survival at 6 months was 84% in patients treated with 
vemurafenib compared to 64% in those who received 
dacarbazine. Vemurafenib was associated with a 63% 
relative reduction in the risk of death. Response to ve-
murafenib occurred rapidly, after a median period of 
1.45 months 9 (15). Unfortunately, the majority of pa-
tients develop resistance to vemurafenib, the median 
duration of response being 5.5-7.5 months (18). 
More recently, in May 2013, a new BRAF protein 
kinase inhibitor dabrafenib and MEK inhibitor tra-
metinib were both approved by the FDA as single 
agents in the treatment of BRAF V600E positive ad-
vanced melanoma. Unfortunately, patients treated 
with these agents as monotherapy developed resis-
tance within 6-7 months (19). Soon afterwards, as 
data from clinical trials showed that combining dab-
rafenib with trametinib overcomes this resistance, 
the combination of the two drugs was granted ac-
celerated approval by the FDA in January 2014 for 
the treatment of unresectable or metastatic mela-
noma demonstrating the BRAF V600E mutation or 
the rarer BRAF V600K mutation, as determined by 
the FDA approved test (19,20). BRAF V600K muta-
tion results in the substitution of valine at codon 600 
to lysine. Combination therapy with dabrafenib 150 
mg daily and trametinib 2 mg daily was compared 
to dabrafenib monotherapy in a phase I/II trial (20). 
The response rate and median progression-free sur-
vival for combination therapy were superior to those 
for monotherapy with dabrafenib (76% vs. 54%; 9.4 
vs. 5.8 months, respectively) (20). Two phase III trials 
that compare combination therapy with dabrafenib 
and trametinib to dabrafenib monotherapy and ve-
murafenib monotherapy, respectively, are currently 
ongoing (21,22).
A series of mucocutaneous side effects have been 
reported with selective BRAF inhibitor therapy, which 
include benign and malignant skin tumors, such as 
keratoacanthoma, and invasive squamous cell carci-
nomas, warty dyskeratomas, and verrucous keratoses 
(23-28). Moreover, some of the patients receiving ve-
murafenib presented with morphological changes in 
preexisting nevi, as well as development of new me-
lanocytic lesions, both benign and malignant (29-37). 
However, few reports on the changes of melanocytic 
nevi under dabrafenib and trametinib treatment have 
been published.
CASE REPORT
We present the case of a 51-year-old Caucasian 
male patient, Fitzpatrick skin type III, diagnosed with 
bilateral axillary lymph nodes metastases of melano-
ma with occult primary tumor in June 2013. Cerebral, 
thoracic, abdominal, and pelvic computed tomogra-
phy examination performed in July 2013 revealed the 
presence of left axillary lymph nodes, left lateral tho-
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racic wall, and bilateral pulmonary metastases. The 
patient tested positive for BRAF V600E mutation. He 
was referred to our Department in August 2013.
The patient presented with an altered general 
state, fatigability, and markedly decreased effort tol-
erance. Clinical examination revealed the presence of 
a firm, violaceous tumorous mass on an erythema-
tous background in the left axillary area (Figure 1). 
Firm nodules of approximately 3 cm in diameter were 
palpable in the right malar and right parasternal re-
gions. 
We noted more than 100 melanocytic nevi on 
the patient’s trunk and limbs (Figure 2), of which 65 
were examined by the aid of digital dermoscopy. The 
dermoscopic pattern of the examined nevi was as fol-
lows: 40 (62%) reticular, 15 (23%) reticular-homoge-
nous, 8 (12%) reticular-globular, and 2 (3%) globular. 
The ophthalmologic examination did not reveal 
pathologic findings. No primary tumor was identi-
fied.
Laboratory analyses yielded leukocytosis (11.5 × 
103/ μL) with neutrophilia (8.52 × 10103/ μL), associ-
ated with a mild biological inflammatory syndrome 
(erythrocyte sedimentation rate (ESR)=36 mm/h, Fi-
brinogen=454 mg/dL and positive C reactive protein 
(CRP)) and an elevated lactate dehydrogenase (LDH) 
level of 648 U/L (normal value <220 U/l). S100 serum 
level was increased at 2.28 μg/L (normal values <0.15 
μg/L determined by chemiluminiscence), while car-
cinoembrionic antigen serum level was 1.52 ng/mL 
Figure 1. Tumorous mass on an erythematous back-
ground in the left axillary area. Figure 2. Numerous nevi on the patient’s torso.
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Table 1. Dermoscopic changes in nevi monitored during vemurafenib, followed by dabrafenib and trametinib 
therapy 
Baseline
number of nevi (%)
Nevi changes during treatment with vemurafenib Nevi changes during treatment with 
dabrafenib and trametinib 
Reticular
40 (62%)
18 presented diffuse decrease in pigmentation 
5 presented new central globules
Further decrease in pigmentation
5 presented central involution
2 eccentric involution
12 presented diffuse increase in pigmentation 
3 presented new central globules
Diffuse decrease in pigmentation
3 presented central involution and 
disappearance of central globules
10 remained unchanged 7 remained unchanged 





9 presented diffuse decrease in pigmentation Further decrease in pigmentation 
4 presented central involution
6 presented diffuse increase in pigmentation Diffuse decrease in pigmentation
5 presented central involution
Reticular-globular
8 (12%)
3 presented diffuse decrease in pigmentation Further decrease in pigmentation and central 
involution
5 presented diffuse increase in pigmentation Diffuse decrease in pigmentation
3 presented central involution
Globular
2 (3%)
Diffuse decrease in pigmentation 1 further decreased in pigmentation
1 remained unchanged
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(normal values <5 ng/mL in non-smokers and <10 
ng/mL in smokers, determined by chemiluminescent 
microparticle immunoassay (CMIA), Architect AB-
BOTT). 
As the patient refused dacarbazine treatment, the 
oncologist initiated treatment with vemurafenib 960 
mg orally q 12 hr. 
After one month of vemurafenib treatment, the 
patient returned to our Department for follow-up skin 
examination. The patient’s general state and effort tol-
erance were very much improved, and the left axillary 
tumorous mass, the right malar and right parasternal 
nodules were no longer present on inspection and 
palpation. Multiple new reticular nevi and seborrheic 
keratoses had occurred. Results of routine laboratory 
exams were within normal limits, as was S100 serum 
level (0.08 μg/L). Computed tomography examina-
tion was repeated in December 2013 and showed the 
resolution of all secondary tumors (left axillary lymph 
Figure 3. Evolution of reticular nevi: (a), (b) diffuse 
decrease in pigmentation during vemurafenib treat-
ment, followed by further decrease in pigmentation 
during dabrafenib and trametinib therapy; (c), (d) dif-
fuse increase in pigmentation during vemurafenib 
treatment, followed by diffuse decrease in pigmen-
tation during dabrafenib and trametinib therapy; 
(e) stable nevus during vemurafenib treatment, fol-
lowed by diffuse decrease in pigmentation during 
dabrafenib and trametinib therapy.
Figure 4. Evolution of reticular-homogenous nevi: 
(a) diffuse decrease in pigmentation and central in-
volution during vemurafenib treatment, followed by 
further decrease in pigmentation during dabrafenib 
and trametinib therapy; (b) diffuse increase in pig-
mentation during vemurafenib treatment, followed 
by diffuse decrease in pigmentation, and central in-
volution during dabrafenib and trametinib therapy.
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Figure 5. Evolution of reticular-globular nevi: (a) dif-
fuse decrease in pigmentation during vemurafenib 
treatment, followed by further decrease in pigmen-
tation during dabrafenib and trametinib therapy; (b) 
diffuse increase in pigmentation during vemurafenib 
treatment, followed by diffuse decrease in pigmenta-
tion, and central involution during dabrafenib and 
trametinib therapy.
nodes, left lateral thoracic wall, and bilateral pulmo-
nary metastases).
Due to financial restraints, vemurafenib admin-
istration was ceased in December 2013. The patient 
was included in an ongoing clinical trial and initiated 
combination therapy with dabrafenib 150 mg/day 
and trametinib 2 mg/day, which he currently re-
ceives. 
The patient’s melanocytic lesions were monitored 
both clinically and dermoscopically throughout ve-
murafenib and dabrafenib and trametinib treatment. 
The changes observed are detailed in Table 1 and il-
lustrated in Figures 3, 4, 5, 6.
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DISCUSSION
The RAS-RAF-MEK-ERK mitogen-activated protein 
kinase (MAPK) pathway is involved in the transduc-
tion of mitogenic signals from the cell membrane to 
the nucleus, influencing cellular differentiation and 
proliferation (38). Hyperactivation of the cascade as 
a result of various mutations occurring at different 
levels leads to uncontrolled cell growth, prevention 
of apoptosis, and promotes cancer development 
(10,39,40). Among such activating mutations, BRAF 
mutations are frequent and have been linked to the 
development of a wide range of malignancies, espe-
cially melanoma and thyroid cancer (16,28). 
Mutant BRAF is present in approximately 50% of 
melanomas and in an even higher proportion of me-
lanocytic nevi (11,12,41). 75-90% of BRAF mutations in 
melanoma are missense mutations resulting from the 
substitution of valine (V) to glutamic acid (E) at codon 
600, referred to as BRAF V600E (10,15). BRAF V600E 
possesses a much amplified kinase activity compared 
to wild-type BRAF and activates downstream mito-
gen-activated protein/extracellular signal-regulated 
kinase (MEK), regardless of RAS status. 
BRAF V600E has become the target of a series of 
new antimelanoma agents, including vemurafenib 
and dabrafenib, with efficacy that greatly exceeds 
that of classic chemotherapeutic drugs as discussed 
above. 
However, these therapies are accompanied by a se-
ries of adverse effects such as arthralgia, rash, fatigue, 
nausea, and diarrhea that impose dose reductions in 
38% of cases (15). Various cutaneous side effects like 
pruritus, alopecia, hyperkeratosis, and the develop-
ment of keratoacanthoma and squamous cell carci-
noma, usually well differentiated, occur frequently in 
patients receiving BRAF kinase inhibitors (15). 
Other phenomena associated with the adminis-
tration of these drugs are morphological changes in 
pre-existing nevi, i.e. changes in size, shape and color, 
both regression or darkening of nevi having been re-
ported (28,30,31), as well as the appearance of new 
benign and malignant melanocytic lesions. These 
changes have been noticed 2 to 42 weeks after start-
ing vermurafenib therapy (29). New primary melano-
mas occurring either in rapidly changing preexisting 
nevi or de novo have been observed in these patients 
(29,33,34,36,42). 
We observed different behaviors of our patient’s 
nevi under vemurafenib treatment. Of the 65 nevi 
monitored, 18 reticular nevi, 9 reticular-homogenous 
nevi, 3 reticular-globular nevi, and 2 globular nevi 
showed a diffuse decrease in pigmentation. 10 re-
ticular nevi remained unchanged, while the rest of 
the nevi, independently of the dermoscopic pattern, 
presented gradual increase in pigmentation. 
Haenssle et al. were the first to report, in 2012, 
involution of pre-existing compound nevi without 
clear dermoscopic signs of immunological regression 
in a 56-year-old woman with BRAF V600E positive 
metastatic melanoma treated with vemurafenib (28). 
Thereafter, several authors described similar changes 
in pigmented lesions during vemurafenib treatment 
(27,34), and it was hypothesized that such involuting 
nevi also harbored BRAF V600E mutation and were 
therefore targeted by vemurafenib (28). 
On the other hand, in the same patient, Haenssle 
et al.  observed a totally different behavior of preexist-
ing flat, reticular pattern nevi under vemurafenib (28). 
These increased in pigmentation, and cytologic dys-
plasia was found in one melanocytic lesion that was 
excised. Such changes in flat nevi were also described, 
among others, by Chu et al. (30), Germani et al. (31), 
and Debarbieux et al. (33). Genetic typing of nevi that 
developed atypical features during vemurafenib treat-
ment revealed non-mutated wild-type BRAF. 
The occurrence of new primary melanomas has 
also been reported in patients receiving vemurafenib. 
Dalle et al. reported 5 new primary melanomas in 4 
of the 5 patients treated (27,34). Similarly, Zimmer et 
al. found 12 new primary melanomas in 11 patients 
under vemurafenib (29). The majority of new primary 
melanomas developed in nevi predating treatment 
with selective BRAF blockers and all proved to be wild-
type BRAF (29,33,34,36,42). It is tempting to speculate 
that these melanomas were biologically present, but 
clinically unapparent before vemurafenib initiation, 
and were revealed by this treatment.
Figure 6. Evolution of globular nevi: (a) diffuse de-
crease in pigmentation during vemurafenib treat-
ment, followed by further decrease in pigmentation 
during dabrafenib and trametinib therapy; (b) diffuse 
decrease in pigmentation during vemurafenib treat-
ment, and stable nevus during dabrafenib and tra-
metinib therapy.
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Transactivation of wild-type BRAF or a paradoxi-
cal activation of the MAP kinase pathway are the 
suspected mechanisms underlying the atypical evo-
lution of reticular nevi and the development of new 
melanomas in these individuals (28,29,34). In vitro 
studies have shown that BRAF inhibitors induce a 
paradoxical MEK activation (13) and a paradoxical 
increase in ERK phosphorylation in wild-type BRAF 
melanocytes (43). The increased signaling through 
the MAP kinase pathway might be related to CRAF 
dependent mechanisms (13). Upregulation of other 
signaling pathways such as PI3K/AKT could also be 
involved in this process.
At the moment there are very few reports on the 
evolution of melanocytic lesions under more recent 
therapies, such as dabrafenib and trametinib combi-
nation therapy. Mattei et al. described a single chang-
ing nevus in a 65-year-old metastatic melanoma male 
patient (32). McClenahan et al. have very recently pub-
lished a report of the BRAFV600E mutation status of 
involuting and stable nevi in a metastatic melanoma 
patient participating in dabrafenib with or without 
trametinib clinical trial. Once again, involuting nevi 
proved to be BRAFV600E, while the stable ones were 
wild type BRAF (44).
Clinical trials showed that dabrafenib and tra-
metinib treatment has less cutaneous side-effects, 
including keratinocyte proliferation, probably due to 
a higher affinity to the mutant BRAF and less cross-
reactivity to CRAF (19). Moreover, the combination 
therapy is accompanied by an even lower risk of skin 
toxicity than monotherapy. This can be explained by 
the inhibition of paradoxical MAP kinase activation 
associated with BRAF inhibitors (45). 
This is in accordance with our findings, with 57 
(88%) of our patient’s nevi showing gradual decrease 
in pigmentation and central involution under dab-
rafenib and trametinib treatment regardless of their 
evolution under vemurafenib treatment. 7 reticular 
nevi and 1 globular nevus remained unchanged. 
None of the monitored nevi increased in pigmenta-
tion nor presented new globules following this com-
bination therapy.
CONCLUSIONS
Systematic total body skin examination, with 
close monitoring of any new or changing pigmented 
lesion is mandatory in patients receiving BRAF inhibi-
tors. The rapid changes of nevi observed under such 
treatments and the increased risk of primary new 
melanomas in these patients necessitate monthly 
follow-up visits. 
The divergent courses of melanocytic nevi during 
vemurafenib vs. dabrafenib and trametinib therapy 
is a matter of great interest that remains to be eluci-
dated by further research.
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